Loading...
•
Mar 31, 2021
Supernus Q1 2021 Earnings Report
Reported financial results for the first quarter of 2021, with total revenues increasing by 38% compared to 2020.
Key Takeaways
Supernus Pharmaceuticals reported a strong first quarter in 2021, with total revenues reaching $130.9 million, a 38% increase compared to the same period in 2020. Net product sales were $128.4 million, a 39% increase year-over-year. The company's operating earnings were $13.2 million, and net earnings were $5.7 million, or $0.11 per diluted share.
Total revenues for Q1 2021 reached $130.9 million, a 38% increase compared to 2020.
Net product sales for Q1 2021 were $128.4 million, 39% higher than the same period in 2020.
Qelbree was approved by the FDA for pediatric ADHD and is on track for a U.S. launch in Q2 2021.
Operating earnings for Q1 2021 were $13.2 million, compared to $29.0 million in Q1 2020.
Revenue by Segment
Forward Guidance
For full year 2021, the Company reiterates its prior financial guidance and added full year 2021 effective tax rate guidance.
Positive Outlook
- Total revenues between $550 million and $580 million.
- Operating earnings between $65 million and $90 million.
- Includes $10 million for QelbreeTM net product sales.
- Effective Tax Rate 28% - 31%
Challenges Ahead
- Combined R&D and SG&A expenses between $380 million and $410 million.
- Operating earnings include amortization of intangible assets and contingent consideration expense.
- The full year 2021 effective tax rate guidance of 28% - 31% is above the normally expected range of 26% - 28% due to the effect of discrete tax items in the period.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...